ОбзорГрафикНовостиTraderScreen

Soc. Generale Bonus Zert PFE 28.0.../  DE000SY20G83  /

Frankfurt Zert./SG
12.11.2024  12:03:45 Изменение+0.080 Бид12:48:27 Предложение- Базовый актив Цена исполнения Дата истечения Тип опциона
26.540EUR +0.30% 26.540
Величина цены спроса: 2,000		 -
Величина цены предложения: -		 Pfizer Inc - USD 28.03.2025 Call
TeleTrader 29.10 Pfizer's Q3 revenue jumps 31% to $17.7 billion
TeleTrader 07.10 Starboard Value allegedly takes $1B stake in Pfizer
TeleTrader 14.09 Pfizer reports positive data from experimental drug study
GlobeNewswire 03.09 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
TeleTrader 27.08 Pfizer launches digital platform to 'simplify' healthcare access
TeleTrader 22.08 FDA okays Moderna, Pfizer updated vaccines
GlobeNewswire 22.08 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire 16.08 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
TeleTrader 30.07 Pfizer's Q2 revenue rises by 2% to $13.3B
GlobeNewswire 17.07 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
TeleTrader 11.07 Pfizer advances once-daily version of weight loss pill
TeleTrader 09.07 Pfizer's chief scientific officer to leave after 15 years
GlobeNewswire 27.06 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire 05.06 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire 03.06 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 16.05 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire 09.05 Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
TeleTrader 01.05 Pfizer's Q1 revenue drops 20% to $14.9 billion
GlobeNewswire 30.04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 22.03 Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire 20.03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 07.03 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 07.03 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 05.03 LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire 28.02 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...